Pharma Stocks In Focus: Semaglutide Opportunities And Revlimid Challenges

The pharmaceutical sector continues to offer opportunities. Business Today TV’s Shailendra Bhatnagar discussed with Vaibhav Sanghavi, CEO of ASK Hedge Solutions, that investors should focus on individual companies rather than broad sector trends. While some firms may face pressure from slowing revenues linked to drugs such as Revlimid, others are positioning themselves for future growth through new products and emerging opportunities like semaglutide. With companies at different stages of regulatory approvals, product cycles, and market exposure, stock selection remains critical. This analysis explores the key trends shaping the pharma industry, the risks investors should watch, and where the next wave of growth could emerge over the next two to four years.